During the past decade, Jing Huang conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Jing Huang" are "Colo-rectal Cancer" (1 trials) and "Esophageal Squamous Cell Carcinoma" (1 trials). Many other conditions were trialed in "Jing Huang" in a lesser frequency.

Most popular intervention types in "Jing Huang" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Anlotinib Hydrochloride with Irinotecan" (1 trials), "Apatinib" (1 trials), "Irinotecan Injection" (1 trials), "Nedaplatin" (1 trials) and "Paclitaxel liposome" (1 trials). Other intervention names were less common.

The vast majority of trials in "Jing Huang" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Jing Huang". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Jing Huang, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Jing Huang, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".